Clinical Leader’s Chief Editor, Ed Miseta, on Caladrius’ type 1 diabetes product candidate, CLBS03, progress through its phase 2 clinical trial.

BioWorld highlights Caladrius’ Sanford Project: T-Rex Study and upcoming milestones.

MD Magazine discusses CLBS03 halfway through enrollment in the Sanford Project: Trex Study with Kurt Grifin, MD, PhD, director of clinical trials for the Sanford Project.

Juvenile Diabetes Cure Alliance details previous CLBS03 study results and how the T regulatory cell technology works.

Close Concerns highlights Caladrius’s CLBS03 product candidate for the recent onset of type 1 diabetes in adolescence and the $12.2 million grant the program received from the California Institute for Regenerative Medicine (CIRM).

Caladrius Chief Executive Officer, Dr. David Mazzo, sits down with CEOCFO Magazine to discuss the Company’s cell therapy development pipeline and CDMO capabilities.

Caladrius Chief Executive Officer, Dr. David Mazzo, discusses the Company’s cell therapy development and CDMO capabilities with Stock News Now’s Shelly Kraft at the Aegis 2016 Growth Conference in Las Vegas.

Caladrius Biosciences recently announced that its product candidate CLBS03 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of type 1 diabetes mellitus (TID), making it the first known therapeutic candidate for T1D to receive the designation.

Caladrius Biosciences has received FDA orphan drug designation for its CLBS03 therapy for people with type 1 diabetes who still have some residual beta cell function.

NeoStem is following two paths, pursuing its own cell therapy pipeline and exploring contract services through its contract development and manufacturing organization (CDMO) subsidiary, Progenitor Cell Therapy (PCT). Click here to read the full article.

Cell therapy manufacturer NeoStem and contract manufacturer Invetech have agreed to develop a new closed processing system for cell therapy manufacturing. Click here to read the full article.

The co-developed system from Invetech and NeoStem will be used to manufacture autologous, patient-specific products in a small-scale process suitable for GMP manufacturing. Click here to read the full article.

Patients who receive more cells get significant benefits. That’s a key lesson emerging from a clinical trial that was reported this week at the American Heart Association meeting in Chicago. Click here to read the full article.

NeoStem’s rapid growth has closely paralleled a shift in medicine over the past decade, in which alternative treatments known as cellular therapy are being developed to tackle cancer, autoimmune disorders and cardiovascular disease. Click here to read the article in full.

Researchers are investigating whether or not another component of the immune system called T regulatory cells, or Tregs, can thwart the aggressive immune response that destroys beta cells, according to Dr. Douglas Losordo, Chief Medical Officer for NeoStem. Click here to read the full article.

Regenerative medicine and cell therapy is sometimes considered the fourth pillar of medicine alongside traditional pharmaceuticals, biologics, and medical devices. PCT holds a unique position as a contract developer and manufacturer that is entirely focused on this rapidly growing market. Click here to read the full article.

NeoStem has positioned itself as a leader in the emerging cellular therapy industry, and opened the door toward launching a critical Phase 3 trial for melanoma, with the acquisition of biotech California Stem Cell (CSC), based in Irvine, California. Click here to read the full article.

Production of patient-specific cell-based therapies (PSCT) presents unique scale and cost challenges not seen in pharmaceuticals and biologics manufacturing. Click here to access the GenEng website.

Cell therapy developer NeoStem has agreed to acquire California Stem Cell in a deal worth up to $124M, and includes CSC’s manufacturing facility in Irvine, CA. Click here to read the full article.

Through the deal, NeoStem will take over development of CSC’s Melapuldencel-T, an autologous melanoma initiating (stem) cell immune-based therapy intended to eliminate the tumor cells capable of causing disease recurrence, beginning with the launch of a pivotal Phase III trial. Click here to read the full article.